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The eﬀects of Buchang Naoxintong Capsules (BNCs) on S-mephenytoin 4 -hydroxylation activities in human liver microsomes in
vitro were assessed. Human liver microsome was prepared by diﬀerent ultracentrifugation. Human liver microsome incubation
experiment was carried out to assay BNC on S-mephenytoin 4 -hydroxylation activities. The 4 -hydroxylation of S-mephenytoin,
a representative substrate toward CYP2C19, was increased by phenytoin sodium (positive control). After the incubation, the meta-
bolites of the substrates (4 -OH-mephenytoin) were determined by HPLC. Results showed that both phenytoin sodium and BNC
showed obvious increase eﬀect on CYP2C19. The enzymatic reaction of BNC was observed with concentrations ranging from
5µg/mL to 250µg/mL. Compared to blank, the increase eﬀect of BNC showed signiﬁcant diﬀerence from the beginning of concen-
tration of 150µg/mL (P<0.001). The conclusion was that BNC showed obvious increase eﬀect on the catalytic activities of drug-
metabolising CYP2C19 enzyme.
1.Introduction
The eﬃcacy of clopidogrel in combination with acetylsali-
cylic acid (ASA) therapy has been clearly established in well-
designed randomized controlled trials that have showed a
reduction in recurrent coronary events following acute myo-
cardial infarction, as compared with ASA monotherapy [1].
However, there is substantial individual variability in res-
ponse to clopidogrel, with inhibition of ADP-induced plate-
let aggregation ranging from less than 10% to almost com-
plete inhibition of platelet aggregation with a wide distri-
bution across this range, such that there is no dichotomous
separation into “responders” and “nonresponders or resis-
tance” [2]. Such variations in response have repeatedly been
associated with adverse cardiovascular outcomes in patients
undergoing percutaneous coronary intervention (PCI) [3].
Thepharmacologyofclopidogreliskeytounderstanding
this phenomenon. Clopidogrel is a prodrug that must be
converted to an active metabolite (R-130964). The meta-
bolite inhibits platelet aggregation (the rationale for clopido-
grel’s use in high-risk cardiovascular disease) by irreversibly
binding to the platelet P2Y12 adenosine diphosphate recep-
tor. In vivo, 85% of the clopidogrel dose is inactivated by
plasma esterases. The remaining 15% is bioactivated in a
2-step pathway that depends on the cytochrome P450 iso-
enzyme system. The speciﬁc isoenzymes involved include
cytochrome P450 1A2, 2B6, 2C9, 2C19, and 3A4 [4]. The
cytochrome P450 2C19 and 3A4 isoenzymes play the major
role.
One mechanism for resistance to clopidogrel involves
genetic polymorphisms that alter expression of cytochrome
P450 isoenzymes that act on the drug. Of these, CYP2C19∗2
is the most common genetic variant reproducibly associated
with variability in clopidogrel active metabolite bioavailabil-
ity, antiplatelet eﬀects, and clinical outcomes [5, 6]. Another
mechanism for clopidogrel resistance is competitive inhibi-
tion of cytochrome P450 isoenzymes needed for the meta-
bolic activation of clopidogrel. To overcome deﬁcits in clopi-
dogrel responsiveness, someone suggested the addition of
CYP inducers to enhance clopidogrel conversion [7]. Our
prevenient study found that adjunctive Buchang Naoxintong
Capsules (BNC) to clopidogrel can enhance the antiplatelet2 Evidence-Based Complementary and Alternative Medicine
eﬀect in volunteers with the CYP2C19∗2g e n em u t a t i o n[ 8].
In the present study, the eﬀect of BNC on the 4 -hydroxylase
activity of S-mephenytoin human liver microsome in vitro
was assessed.
2.MaterialsandMethods
2.1. Drugs. BNC 0.4g (Compilation of The National Stan-
dard of Chinese Traditional Medicine no. WS-10001 (ZD-
0001)-2002;Med-drugPermitno.Z20025001)weresupplied
by the Buchang Pharmaceutical Co. Ltd. The ingredients of
BNC include Radix Astragali, Radix Angelicae Sinensis,
Radix Paeoniae Rubra, Radix Salviae Miltiorrhizae, Rhizoma
Chuanxiong,SemenPersicae,FlosCarthami,ResinaOlibani,
Myrrha, Caulis Spatholobi, Radix Achyranthis Bidentatae,
Ramulus Cinnamomi, Ramulus Mori, Pheretima, Scorpio,
and Hirudo.
BNC was ﬂayed, triturated, quantiﬁed, and then was
dissolved in dimethylsulfoxide (Tianjin Fuchen Chemical
Reagents Factory, concentration less than 1/1000).
2.2. Human Liver Microsomes. The ten human liver samples
were obtained from patients who underwent a partial hepa-
tectomy at the Department of Hepatobiliary Surgery, Fujian
ProvincialHospital(Fuzhou,China).Surgerywasperformed
for the removal of liver trauma from the liver. The use of the
human liver for the study had been approved by the Institu-
tionalEthicsCommittee.Noneofthesubjectshadareported
history of alcohol or drug abuse. The livers were remo-
vedwithin2h,frozeninliquidnitrogen,andstoredat −80◦C
until used for microsomal preparation. Liver microsomes
were prepared by diﬀerent ultracentrifugation as described
previously [9]. Liver samples are homogenized and cen-
trifuged at a lower force (9000r/min) for 15min. The
resulting supernatant is then centrifuged at a higher force
(100000r/min) for 60min to precipitate the microsomes.
The microsomal is resuspended in a ﬁnal suspension buﬀer
and is then ready for use in incubation studies. Protein and
CYP contents were determined using the Bradford Protein
Assay Kit (Shanghai Majorbio Bio-Pharm Technology Co.
Ltd) and the method of Omura and Sato [10], respectively.
The concentration of the protein in liver microsomes was
18mg/mL, and the total amount of CYP450 enzyme was
589pmole/mg.
2.3. Incubation Conditions. Microsomes (0.5mg protein)
wereincubatedat37◦Cfor60minwith20µLS-mephenytoin
(250µmol/L, sigma company, black group) and an NADPH
(Sigma-Aldrich Co. Ltd, Shanghai) generating system in the
presence or absence of 20µL BNC (trial group) or 20µL phe-
nytoin sodium [an inducer of the CYP2C19 enzyme (http://
drugs.medsort.com/), sigma company, 15µg/mL (0.3µg/mL
as the incubation ﬁnal concentration), positive control
group]inaﬁnalvolumeof1mL.BNCwasdissolvedindime-
thylsulfoxide (Tianjin Fu Chen Chemical Reagents Factory)
and added to the incubation mixture of microsomes.
The incubation ﬁnal concentrations of BNC used were
5µg/mL, 50µg/mL, 100µg/mL, 150µg/mL, 200µg/mL, and
250µg/mL. The same volume of dimethylsulfoxide was
added to the black group and positive control group. One
sample was divided into ﬁve tubes. Adding 3mL cold dich-
loromethane (Hao Fly Chemical Co. Ltd, Zhengzhou), the
reactionwasterminatedbycooling onice.100µLphenacetin
(2.795µg/mL, sigma company) was added as an internal
standard. The mixture was shaken for 5min, then centrifu-
ged at 2000g for 10min. The upper organic phase was trans-
ferred to another tube and evaporated to dryness under nit-
rogen. The residue was dissolved in 100µLo fe l u a t ea n d
20µL was injected into Agilent 1200 high-performance liq-
uid chromatography (HPLC, Agilent Technologies Co. Ltd,
USA) system.
2.4. Determination of 4 -Hydroxymephenytoin. 4 -Hydroxy-
mephenytoin was purchased from Research Biochemicals
International (Natick, MA). Determination of 4 -hydroxy-
mephenytoin was carried out by the HPLC method as repor-
ted previously [8]. The mobile phase consisted of methyl
alcohol, acetonitrile, and water pH value was adjusted to 8.0
by triethylamine (Hou Wang Chemical Co. Ltd, Nanjing) in
the proportion of 17/19/64 and was delivered to a Welchrom
C18 column (Shiseido Co. Ltd, Tokyo, Japan; 4.6mm ×
250mm, 5µm) at a column temperature of 25◦Ca n daﬂ o w
rate of 1.0mLmin−1. The eluate was monitored at a wave-
length of 204nm. The calibration curve was generated by
processing the authentic standard substance through the en-
tire procedures. The coeﬃcient of variation for the intraassay
and inter-assay was less than 3.75% and 4.41%, respectively.
2.5. Statistical Analysis. Data were analyzed using SPSS (ver-
sion 16.0, SPSS Inc., America) and expressed as mean and
SD. Analysis of variance (ANOVA) was used as statistical
methods to compare group means. A value of P<0.05 was
considered to indicate statistical signiﬁcance.
3. Results
3.1. Chromatogram. Figures 1(a), 1(b),a n d1(c) show chro-
matogram of buﬀer solutions blank, chromatogram of
4 -OH-mephenytoin, phenacetin, and S-mephenytoin, and
chromatogram of incubated microsomes sample, respec-
tively.
3.2. Accuracy. The results from the accuracy studies are give
in Table 1.
3.3. Recovery Studies (Table 2). The extraction recovery was
given in Table 2. The absolute recovery of 4 -OH-mepheny-
toin at the three levels of 230, 2300, and 5800ng/mL ranged
from 96.3 to 98.2%.
3.4. Linear Range and Detection and Detection Limit
(Figure 2). A linear calibration graph was obtained for 4 -
OH-mephenytoin in the range 70.5–5800ng/mL with a cor-
relation coeﬃcient (r2) of 0.9969. The regression equation
waswrittenas Y = 2678.1X+93.9.Thismethod hadalimit
of detection of Ca. 39.1ng/mL.Evidence-Based Complementary and Alternative Medicine 3
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Figure 1: Chromatogram of buﬀer solutions blank (a), chromatogram of 4 -OH-mephenytoin (7.0min), phenacetin (12.8min), and S-me-
phenytoin (19.1min (b)), and chromatogram of incubated microsome sample (c), respectively.
Table 1: Precision of the determination of 4 -OH-mephenytoin (mean ± SD, n = 5).
Joined concentration (ng/mL) Intraday (ng/mL) RSD (%) Interday (ng/mL) RSD (%)
230 227.00 ±8.52 3.75% 227.83 ± 10.05 4.41%
2300 2278.30 ±58.60 2.57% 2269.30 ±77.19 3.40%
5800 5849.30 ±122.44 2.09% 5779.30 ± 141.53 2.45%
Table 2: The extraction recovery of 4 -OH-mephenytoin (mean ±
SD, n = 5).
Joined concentration Extraction recovery (%) RSD (%)
(ng/mL)
230 98.2 ±4.34 . 4 %
2300 96.3 ±3.94 . 0 %
5800 97.7 ±2.541 2.6%
3.5. The Eﬀects of BNC on S-Mephenytoin 4 -Hydroxylation
ActivitiesinHumanLiver Microsomes. Comparedwithblank
group, the amount of 4 -OH-mephenytoin was signiﬁcantly
increased in positive control group and trial group after pre-
incubated with phenytoin sodium (0.3µg/mL, P<0.000)
and BNC from the beginning of concentration of 150µg/mL
(P<0.001, Table 3) in human liver microsomes. The pro-
duction rates of 4 -OH-mephenytoin in black group were
deﬁned as 100%, these production rates of 150µg/mL,
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Figure 2: Standard curve of 4 -OH-mephenytoin.
200µg/mL and 250µg/mL were increased 8.6%, 11.1%, and
12.9%, respectively.4 Evidence-Based Complementary and Alternative Medicine
Table 3: Comparison of the amount of 4 -OH-mephenytoin among blank group, positive control group, and trial group.
Blank group
(n = 5)
Positive
control group
(phenytoin
sodium,
n = 5)
Trial group (BNC, n = 5)
Incubation ﬁnal
concentration
(µg/mL)
0.3 5 50 100 150 200 250
4 -OH-M
(nmol/mg·h) 6.8 ±0.37 .7 ±0.36 .6±0.46 .8±0.37 .1±0.37 .3 ± 0.47 .5 ±0.37 .6 ±0.2
 ,

,♀ ,

,♀♀,† ,

,♀♀♀,††
Note: values are presented as mean ± SD.
,

, ♀♀♀: compared with blank, 5µg/mL, 50µg/mL, 100µg/mL, respectively, P<0.000.
,

, ♀♀, ††: compared with blank, 5µg/mL, 50µg/mL, 100µg/mL, respectively, P<0.001.
♀, †: compared with 5µg/mL, 50µg/mL, respectively, P<0.05.
4. Discussion
The active metabolite (R-130964) of clopidogrel is a sec-
ondary metabolite, and multiple cytochrome P450 enzymes
(CYPs),includingCYP3A,CYP2C19,CYP2C9,CYP2B6,and
CYP1A2, contribute to the two sequential metabolic steps
resulting in the formation of R-130964. Of these, CYP2C19
is responsible for approximately 45% of the ﬁrst step (the
formation of 2-oxo-clopidogrel) and approximately 20%
of the ﬁnal step—the generation of the pharmacologically
active thiol metabolite. CYP2C19 also is a major metaboliz-
ing enzyme of several clinically important drugs such as pro-
ton-pump inhibitors (PPIs) like omeprazole and lanzopra-
zole, antiepileptics-like mephenytoin, diazepam, and selec-
tive serotonin reuptake inhibitors like citalopram. PPIs are
often given concomitantly with clopidogrel to minimize the
chances of gastrointestinal bleeding in patients with acute
coronary syndrome especially percutaneous coronary inter-
ventions. Recent attention has been placed on a potential
interaction observed between clopidogrel and the widely
used PPIs. Some evidence suggested that omeprazole inter-
acted with clopidogrel, reducing clopidogrel antiplatelet
eﬀects as measured by various laboratory tests [11, 12]. Most
data indicated that the interaction involves the competitive
inhibition of the CYP2C19 isoenzyme. The interaction ap-
pears to be clinically signiﬁcant, as several retrospective ana-
lyses have shown an increase in adverse cardiovascular out-
comes when PPIs and clopidogrel are used concomitantly
[13–15].
Bent evaluated in vitro the dose-dependent induction
potential of six commonly used trade herbal products on
CYP2C19 and CYP2E1 metabolic activities in cultured hu-
man hepatocytes. They found that St John’s wort was the
most potent CYP-modulating herb, showing a dose-depen-
dent induction/inhibition of CYP2C19, with induction at
low dosages and inhibition at higher ones [16]. Previous
investigations in man have shown that CYP2C19 activity
is susceptible to induction by herbs and natural products;
examples include St John’s wort, G. biloba and the Chinese
herbal mixture Yin Zhi Huang (also called Jaundiclear)
[17–19]. Induction of cytochrome P450 isoenzymes, leading
to an enhanced platelet inhibitory eﬀect of clopidogrel,
has also been described, which suggests a means for
overcoming clopidogrel resistance. In a small prospective
study, administration of St John’s wort enhanced the platelet
inhibitory eﬀect of clopidogrel in volunteers known to
be unresponsive to the drug and in patients with stable
coronary artery disease [20]. Their further studies suggested
that St John’s wort on the pharmacodynamic response of
clopidogrel in hyporesponsive volunteers and patients could
increase platelet inhibition by enhancement of CYP3A4
metabolic activity [21]. Our study showed that BNC showed
obvious increase eﬀect on the catalytic activities of drug
metabolism CYP2C19 enzyme. The increase eﬀect of BNC
was from the beginning of concentration of 150µg/mL.
This result might explain why adjunctive BNC to clopido-
grel can enhance the antiplatelet eﬀect in volunteers with
the CYP2C19∗2 gene mutation. It was important clinical
meaning. In China, BNC is an approved traditional Chinese
medicine (TCM) for stroke [22], which is widely used, and
is well tolerated. BNC combined with aspirin could enhance
the antiplatelet eﬀect in patients with cardio-cerebrovascular
diseases [23], but there is a lack of study of possible drug-
herb interactions. Our current study showed that BNC
combined dual antiplatelet therapy (DA, clopidogrel plus
ASA) enhanced the anti-microembolization (CME) eﬀect
of either therapy alone and reduced the risk of the DA
therapy-associated bleeding, demonstrating an improved
beneﬁt/risk ratio in the rat model of CME by inhibiting
platelet aggregation and myocardial apoptosis, balance the
pro- and anti-inﬂammatory cytokines as well as serum ET-1
and eNOS [24, 25]. This result suggested that integrated
Chinese and Western medicine might provide a multitarget
therapy with potential superior therapeutic eﬃcacy and a
better safety proﬁle.
Understanding drug interactions that impair or increase
therapeutic eﬃcacy is important, especially with multidrug
treatment. Although our ﬁndings are provocative, futureEvidence-Based Complementary and Alternative Medicine 5
studies designed to investigate the BNC on CYP2C19 meta-
bolic activities in vivo experimental methods.
5. Conclusions
BNCshowedobviousincreaseeﬀectonthecatalyticactivities
of drug metabolism CYP2C19 enzyme. The eﬀect of BNC
begins from the beginning of concentration of 150µg/mL.
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